コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 patients receiving combination treatment or interferon alfa-2a.
2 compared peginterferon alfa-2a (40 kd) with interferon alfa-2a.
3 1 IU/mL before the introduction of pegylated interferon alfa-2a.
4 sed double-blind placebo-controlled trial of interferon alfa-2a (10 million units/m2, daily for 7 day
6 trial involving 674 patients, the effect of interferon alfa-2a (3 megaunits three times per week for
7 day), peginterferon alfa-2a plus placebo, or interferon alfa-2a (3 million IU three times a week) plu
8 days, then 750 mg/m2 weekly, and recombinant interferon alfa-2a 9 million units subcutaneously three
9 r 90 mug/week (for arm B) of pegylated (Peg) interferon alfa-2a added to their current ART regimen.
12 ined virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepati
13 llocated (1 to 1) by minimisation to receive interferon alfa-2a alone or combination therapy with int
14 l or progression-free survival compared with interferon alfa-2a alone, immunotherapy might still have
15 ere reported in 113 (23%) patients receiving interferon alfa-2a and 131 (26%) of those receiving comb
16 2 patients were randomly assigned to receive interferon alfa-2a and 504 to receive combined treatment
19 jection (CR) in patients receiving pegylated interferon alfa-2a and ribavirin (PEG) to treat recurren
20 8), telaprevir in combination with pegylated interferon alfa-2a and ribavirin (Peg-IFN/RBV) for 15 da
21 zed 1:1:2:2 to receive 24 weeks of pegylated interferon alfa-2a and ribavirin (PegIFN/RBV) in combina
22 th TMC435 (200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFNalpha-2a and RBV
23 (Virahep-C), 260 men treated with pegylated interferon alfa-2a and ribavirin completed self-administ
25 ng recombinant interleukin-2 and recombinant interferon alfa-2a before and after combination cytotoxi
26 d) provides improved sustained response over interferon alfa-2a, but its effect on HRQL is unknown.
29 owledge, the antiviral activity of pegylated interferon alfa-2a has not been studied in participants
31 e maximum-tolerated dosage (MTD) of IL-2 and interferon alfa-2a (IFN alpha-2a) that can be administer
33 etyl-L-aspartic acid (PALA), and recombinant interferon alfa-2a (IFNalpha-2a) in a sequential order t
35 rapy with 13-cis-retinoic acid (13-CRA) plus interferon alfa-2a (IFNalpha2a) is superior to IFNalpha2
37 afety and efficacy of REP 2139 and pegylated interferon alfa-2a in patients with chronic HBV and hepa
39 astatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil prod
40 on alfa-2a alone or combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil.
44 REP 2139 and 180 mug subcutaneous pegylated interferon alfa-2a once per week for 15 weeks, then mono
47 patitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV)
48 We conducted a phase II study of pegylated interferon alfa-2a (PEG-IFN-alpha-2a) in patients with e
49 of sofosbuvir (SOF), ribavirin (RBV) and peg-interferon-alfa-2a (peg-IFN-alfa-2a) as well as the comb
50 -label subcutaneous treatment with pegylated interferon-alfa-2a (Peg-IFNalfa-2a) 180 mug/wk, or albIF
51 ompared the efficacy and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either r
52 of sofosbuvir in combination with pegylated interferon alfa-2a (peginterferon) and ribavirin in non-
53 plus ribavirin than among those assigned to interferon alfa-2a plus ribavirin (40 percent vs. 12 per
54 a lower likelihood of SVR than was pegylated interferon alfa-2a plus ribavirin (absolute difference,
55 us either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of c
56 was significantly more effective than either interferon alfa-2a plus ribavirin or peginterferon alfa-
59 imeprevir (150 mg once daily) with pegylated interferon alfa-2a/ribavirin (peg-IFN/RBV) for 12 weeks.
60 ERPRETATION: Combined REP 2139 and pegylated interferon alfa-2a therapy is safe, well tolerated, and
61 cts were assigned to receive 6 million IU of interferon alfa-2a three times weekly for 12 weeks follo
62 .8 months (17.0-23.2) for patients receiving interferon alfa-2a versus 18.6 months (16.5-20.6) for th
64 After 5 weeks, ART was interrupted, and Peg-interferon alfa-2a was continued for up to 12 weeks (the
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。